期刊
CELL REPORTS
卷 4, 期 1, 页码 135-147出版社
CELL PRESS
DOI: 10.1016/j.celrep.2013.06.008
关键词
-
类别
资金
- Leukaemia and Lymphoma Research [08040, 08068]
- Wellcome Trust core award [090532/Z/09/Z]
- Medical Research Council (MRC)
- Department of Health's NIHR Biomedical Research Centres
- Medical Research Council [G1000801c, G1000801d, MC_U137961142, G1000729, MC_UU_12009/8, MC_UU_12009/9, MC_U137981013, G1000801a, MC_U137961146, MC_UU_12009/11] Funding Source: researchfish
- MRC [MC_UU_12009/9, MC_UU_12009/11, MC_UU_12009/8, MC_U137981013, MC_U137961142, G1000729, MC_U137961146] Funding Source: UKRI
Cell fate is governed by combinatorial actions of transcriptional regulators assembling into multiprotein complexes. However, the molecular details of how these complexes form are poorly understood. One such complex, which contains the basic-helixloop-helix heterodimer SCL:E47 and bridging proteins LMO2:LDB1, critically regulates hematopoiesis and induces T cell leukemia. Here, we report the crystal structure of (SCL: E47)(bHLH):LMO2:LDB1(LID) bound to DNA, providing a molecular account of the network of interactions assembling this complex. This reveals an unexpected role for LMO2. Upon binding to SCL, LMO2 induces new hydrogen bonds in SCL:E47, thereby strengthening heterodimer formation. This imposes a rotation movement onto E47 that weakens the heterodimer: DNA interaction, shifting the main DNA-binding activity onto additional protein partners. Along with biochemical analyses, this illustrates, at an atomic level, how hematopoietic-specific SCL sequesters ubiquitous E47 and associated cofactors and supports SCL's reported DNA-binding-independent functions. Importantly, this work will drive the design of small molecules inhibiting leukemogenic processes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据